Sector News

Lundbeck may buy GSK drugs to complement portfolio: Sydbank

October 15, 2014
Life sciences
(Reuters) – Danish pharmaceutical group Lundbeck (LUN.CO) is one of the potential bidders for some of the older products worth in total $3 billion that British GlaxoSmithKline (GSK.L) is looking to divest, according to sources.
 
Lundbeck is reviewing a bid for products marketed in North America as it seeks to expand there, two sources told Reuters.
 
Shares in Lundbeck are traded 2.1 percent higher on Wednesday at 1045 GMT (0645 EDT) outperforming a 0.6 percent fall in the Danish benchmark index .OMXC20CAP.
 
Analysts made the following comments:
 
ANALYST SOREN LONTOFT HANSEN, SYDBANK
 
“Lundbeck could be looking at drugs that could complement its existing drug portfolio. We have seen that before, for example when the company bought Chelsea Therapeutics International, whose neurodrug Northera had just been approved in the United States.
 
“The patents expire on some of Lundbeck’s most significant products these years. The company has some of its own developed products as Selincro and Brintellix, and with the Japanese partner Otsuka it has Abilify Maintena. But it takes time to penetrate the market for these drugs, so I think Lundbeck is also looking for alternatives which can complement the existing pipeline, and where it makes sense for their salesmen also to have these drugs with them, when they visit customers”.
 
“Lundbeck has built a decent business in North America on drugs for some relatively rare diseases and they are still building on that what with Abilify Maintena and Brintellix”.
 
“There’s a giant potential on the U.S. market. It makes sense to use the existing sales force to take on a few more drugs. So it will probably be some drugs that complements some of Lundbeck’s existing drugs.”
 
(Reporting by Teis Jensen; editing by Sabina Zawadzki)

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.